This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Lenvatinib | |
|---|---|
| Drug name | Lenvatinib |
| Routes of administration | Oral |
| Metabolism | Hepatic, renal |
Lenvatinib is a small-molecule tyrosine kinase inhibitor approved for multiple oncologic indications involving solid tumors and endocrine malignancies. It is indicated for treatment of differentiated thyroid carcinoma, hepatocellular carcinoma, and renal cell carcinoma in combination with other agents, and has been evaluated across multiple clinical trials and regulatory reviews. Major regulatory approvals and guideline endorsements have influenced its adoption in oncology practice at academic centers and cancer networks.
Lenvatinib is approved for radioiodine-refractory differentiated thyroid carcinoma, hepatocellular carcinoma after sorafenib, and in combination with Pembrolizumab for advanced renal cell carcinoma and recurrent or metastatic endometrial carcinoma, with approvals granted following pivotal trials reviewed by agencies such as the U.S. Food and Drug Administration, the European Medicines Agency, and national health authorities in Japan. Clinical efficacy has been demonstrated in randomized controlled trials versus comparators including Placebo arms and active agents, with primary endpoints often encompassing progression-free survival and overall response rate assessed by committees influenced by standards from the National Comprehensive Cancer Network, the American Society of Clinical Oncology, and cooperative groups. Off‑label and investigational uses have included combinations with immune checkpoint inhibitors studied in multicenter trials sponsored by academic institutions, industry consortia, and cooperative oncology groups such as the European Organisation for Research and Treatment of Cancer.
Lenvatinib exerts antitumor activity through inhibition of multiple receptor tyrosine kinases implicated in angiogenesis and tumor proliferation, targeting VEGFRs, FGFRs, PDGFRα, RET, and KIT; these targets overlap with pathways studied in basic research at institutions like the Dana‑Farber Cancer Institute, the Memorial Sloan Kettering Cancer Center, and university laboratories. Its pharmacokinetic profile includes oral absorption, hepatic metabolism involving cytochrome P450 pathways characterized in pharmacology groups at universities and pharmaceutical departments, and renal elimination patterns evaluated in clinical pharmacology studies overseen by regulatory agencies and pharmacokinetic consortia. Preclinical models from academic centers and biotechnology companies demonstrated antiangiogenic effects in xenograft studies and informed dose selection used in phase I–III trials coordinated with clinical research organizations and oncology trial networks.
Common adverse reactions observed in pivotal studies and postmarketing surveillance include hypertension, proteinuria, fatigue, diarrhea, decreased appetite, and weight loss; safety signals were characterized in data reviews by the Pharmacovigilance Risk Assessment Committee and regulatory safety communications. Serious toxicities reported in trials and case series include hepatotoxicity, arterial thromboembolic events, gastrointestinal perforation, and hemorrhage, with monitoring recommendations echoed by professional societies such as the American Thyroid Association, the European Society for Medical Oncology, and the Society of Gynecologic Oncology. Management of adverse effects often involves involvement of multidisciplinary teams at tertiary centers, input from specialists in nephrology, cardiology, hepatology, and supportive care programs affiliated with cancer centers and university hospitals.
Dosing regimens authorized by regulatory agencies vary by indication, with starting doses and adjustments informed by trials conducted at research networks and academic cooperative groups; typical initiation for differentiated thyroid carcinoma and hepatocellular carcinoma follows fixed oral daily dosing with modifications for tolerability in real‑world practice guided by institutional protocols at comprehensive cancer centers. Administration guidance includes instructions for dose interruptions and reductions based on laboratory monitoring and clinical assessment, implemented through oncology pharmacy services, hospital formularies, and treatment pathways developed by multidisciplinary committees at cancer institutes. Patient selection, baseline evaluations, and follow‑up schedules reflect recommendations found in clinical guidelines from organizations including the National Institute for Health and Care Excellence and national oncology societies.
Contraindications and precautions derive from clinical trial exclusion criteria and pharmacovigilance reports; caution is advised in patients with uncontrolled hypertension, significant cardiac disease evaluated by cardiology services, active bleeding or high‑risk lesions managed in tertiary hospitals, and severe hepatic impairment assessed by hepatology teams. Use during pregnancy and lactation is contraindicated due to embryofetal toxicity observed in preclinical studies and discussed in regulatory labeling reviewed by panels at the U.S. Food and Drug Administration and the European Medicines Agency; contraception counseling is typically coordinated with obstetrics and gynecology specialists.
Lenvatinib exposure can be influenced by concomitant medications that affect cytochrome P450 enzymes and P‑glycoprotein transporters identified in pharmacology research at academic centers and pharmaceutical companies; interactions with strong CYP3A4 inducers or inhibitors, as catalogued by drug interaction compendia used in hospital pharmacies and clinical pharmacology services, may alter plasma concentrations. Concomitant use with anticoagulants and antiplatelet agents increases bleeding risk noted in clinical registries and case reports managed by hematology departments; combinations with other antiangiogenic agents or cytotoxic chemotherapies require coordination among oncology, pharmacy, and trial oversight committees to mitigate overlapping toxicities.
Lenvatinib was discovered and developed by a pharmaceutical company with clinical development programs conducted across global trial sites and academic centers, proceeding from preclinical kinase profiling in laboratory collaborations to first‑in‑human studies run by early‑phase units at major cancer centers, and later randomized pivotal trials submitted to regulatory authorities such as the U.S. Food and Drug Administration and the European Medicines Agency. The drug's clinical development included partnerships with cooperative research groups, academic investigators, and regulatory advisory committees, leading to label expansions and guideline incorporation following publications in peer‑reviewed journals and presentations at major conferences like the American Society of Clinical Oncology annual meeting and the European Society for Medical Oncology Congress.
Category:Antineoplastic drugs